Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
prethcamide
- Development stage
- Unknown
- Lead developer
- Novartis
- Modality
- Small Molecules
- Administration
- Oral, Intravenous, Intramuscular
01
Overview
Prethcamide is a respiratory stimulant composed of two related drugs, cropropamide and crotethamide, in equal parts. It acts as a central and peripheral respiratory stimulant by stimulating peripheral chemoreceptors and central respiratory centers. The drug has pressor effects and may increase catecholamine release. Prethcamide is used primarily to treat respiratory depression or insufficiency. Its action is described as mild, somewhat inconstant, slow in onset but prolonged in duration, with potential for unpleasant side effects. It was developed by Ciba-Geigy.
- Brand names
- MicorenRestimulen
- Other names
- prethcamide
Beyond the preview
Go deeper on prethcamide.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on prethcamide.